Method for quantitative assessment of protective immunity against SARS-CoV-2, its duration and antibody dynamics

The level and duration of protective immunity are often analyzed qualitatively or semi-quantitatively. The same strategy is applied to the analysis of antibody dynamics. At some point in time t after exposure or immunization, the presence of immunity against the infection is inferred from the level of specific antibodies by comparing it to a reference value. This approach does not account for the stochastic nature of human disease after exposure to a pathogen. At the same time, it is not fully clear what antibody level should be considered protective. The aim of this study was to develop a mathematical model for quantitative determination of protective immunity against SARS-CoV-2 and its duration. We demonstrate that the problem of describing protective immunity in quantitative terms can be broken down into 2 interrelated problems: describing the quantitative characteristics of a pathogen’s virulence (in our case, the pathogen is SARS-CoV-2) and describing the dynamics of antibody titers in a biological organism. Below, we provide solutions for these problems and identify parameters of the model which describes such dynamics. Using the proposed model, we offer a theoretical solution to the problem of protective immunity and its duration. We also note that in order to quantitatively determine the studied parameters in a homogenous population group, it is necessary to know 5 parameters of the bivariate probability density function for correlated continuous random variables: the infective dose of the pathogen and the antibody titer at which the disease develops and which are still unknown.

1. Ye Q., Wang B., Mao J., Fu J., Shang S., Shu Q., et al. Epidemiological analysis of COVID-19 and practical experience from China. J Med Virol. 2020 Jul; 92 (7): 755–69. DOI: 10.1002/jmv.25813. Epub 2020 Apr 10. PMID: 32237160; PMCID: PMC7228220.

2. Li K., Huang B., Wu M., et al. Dynamic changes in anti-SARSCoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19. Nat Commun 11, 6044 (2020). Available from: https://doi.org/10.1038/s41467-020-19943-y.

3. Sun B., Feng Y., Mo X., Zheng P., Wang Q., Li P., et al. Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients. Emerg Microbes Infect. 2020 Dec; 9 (1): 940–8. DOI: 10.1080/22221751.2020.1762515. PMID: 32357808; PMCID: PMC7273175.

4. Karmishin A.M., Borisevich I.V., Kruglov A.A., Nosov N.Yu., Postupajlo V.B., Zhigarlovskij B.A., i dr. Teoreticheskie aspekty modelirovanija jepidemii COVID-19. VV RHB zashhity. 2020; 4 (90): 73–88. Russian.

5. Postupajlo V.B., Karmishin A.M., Nosov N.Yu., Zhigarlovskij B.A.; zajavitel' i pravoobladatel'. Sposob opredelenija kolichestvennyh harakteristik processa inficirovanija naselenija SARS-CoV-2 v razlichnyh stranah. Svidetel'stvo o gosudarstvennoj registracii bazy dannyh # 2021620762 Rossijskaja Federacija; zjavl. 05.04.2021; gosregistracija 16.04.2021. Russian.

6. Karmishin A.M., Gumenjuk V.I., Makarov M.L. Teoreticheskie aspekty obosnovanija kolichestvennyh pokazatelej opasnosti avarij potencial'no opasnyh promyshlennyh ob"ektov. Problemy bezopasnosti i chrezvychajnyh situacij 2019; 2: 51–66. Russian.

7. Karmishin A.M., Borisevich I.V., Skvorcova V.I., Gorjaev A.A., Judin S.M. Verojatnost' vozniknovenija infekcionnogo zabolevanija cheloveka pri jepidemii. Medicina jekstremal'nyh situacij. 2021; 1: 5–11. DOI: 10.47183/mes.2021.007. Russian.

8. Lei Q., Li Y, Hou H.Y., et al. Antibody dynamics to SARS–CoV–2 in asymptomaticCOVID–19infections. Allergy. 2021; 76: 551–61. Aailable from: https://doi.org/10.1111/all.14622.

9. Dronina A.M., Guzovskaja T.S., Severinchik I.V., Bandackaja M.I., Chistenko G.N. Osnovy immunoprofilaktiki: uchebno-metodicheskoe posobie. Minsk: BMGU, 2019; 138 s. Russian.

10. Instrukcija po medicinskomu primeneniju lekarstvennogo preparata Gam-KOVID-Vak. Kombinirovannaja vektornaja vakcina dlja profilaktiki koronavirusnoj infekcii, vyzyvaemoj virusom SARS-CoV-2. Aailable from: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=44bf0ff3-f94e-4c42-954ea4c53811576c&t. (Ssylka aktivna na 22 aprelja 2021). Russian.

11. Instrukcija po medicinskomu primeneniju lekarstvennogo preparata «JepiVakKorona». Vakcina na osnove peptidnyh antigenov dlja profilaktiki COVID-19. Dostupno po ssylke: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=fa7efa73-4f93-4e05-b467-03998160616d&t. (Ssylka aktivna na 22 aprelja 2021). Russian.

12. REG 174 information for UK healthcare professionals. Aailable from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/978194/uk-HCPcovid-19-vaccine-astrazeneca-reg174_proposed_14_Apr_2021.pdf. (Ссылка активна на 22 апреля 2021).

13. Fact sheet for recipients and caregivers emergency use authorization (EUA) of the Moderna covid-19 vaccine to prevent coronavirus disease 2019 (COVID-19) in individuals 18 years of age and older. Aailable from: https://www.modernatx.com/covid19vaccine-eua/eua-fact-sheet-recipients.pdf. (Ссылка активна на 22 апреля 2021).

14. Fact sheet for recipients and caregivers emergency use authorization (EUA) of the Pfizer-BioNTech COVID-19 Vaccine to prevent Coronavirus Disease 2019 (COVID-19) in individuals 16 years of age and older. Aailable from: https://www.fda.gov/media/144414/download. (Ссылка активна на 22 апреля 2021).

15. Karmishin A.M., Kireev V.A., Berezin G.I., Afanasev R.V. Matematicheskie metody farmakologii, toksikologii i radiobiologii. M.: OOO «APR», 2011; 330 s. Russian.

16. Karmishin A.M. K voprosu o bezopasnoj doze toksichnyh himicheskih veshhestv. V sbornike: V. R. Rembovskij, redaktor. Materialy Vserossijskoj nauchno-prakticheskoj konferencii, posvjashhennoj 55-letiju FGUP «NII GPJeCh» FMBA Rossii, 17 fevralja 2017 g., g. Sankt-Peterburg. SPb.: Izd. Politehn. un-ta, 2017; s. 64–66. Russian.

17. Karmishin A.M., Nosov N.Yu., Zhigarlovskij B.A., Postupajlo V.B. Bezopasnaja doza toksichnyh himicheskih veshhestv. V sbornike: Materialy I Nacional'nogo kongressa s mezhdunarodnym uchastiem po jekologii cheloveka, gigiene i medicine okruzhajushhej sredy «SYSINSKIE ChTENIJa — 2020» Moskva, 19-20 nojabrja 2020 g. M.: FGBU «CSP» FMBA Rossii, 2020; s. 168–72. Russian.

18. Kombarova S.Yu., Aleshkin A.V., Novikova L.I., Bochkareva S.S., Karpov O.Ye., Pulin A.A., i dr. Dinamika antitel k razlichnym antigenam koronavirusa SARS-CoV-2 u bol'nyh s podtverzhdennoj infekciej Covid-19. 2020. COVID19-PREPRINTS.MICROBE.RU. Dostupno po ssylke: https://doi.org/10.21055/preprints-3111756. Russian.

19. Popova A.Yu., Ezhlova E.B., Melnikova A.A., Andreeva E.E., Kombarova S.Yu., Ljalina L.V., i dr. Kollektivnyj immunitet k SARS-CoV-2 zhitelej Moskvy v jepidemicheskij period COVID-19. Infekcionnye bolezni. 2020; 18 (4): 8–16. DOI: 10.20953/1729-9225-2020-4-8-16. Russian.